Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rev-5901 SCHEMBL29369872 | 1.00 | GPBAR1 (1.00) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10638786 | 0.99 | CYSLTR1 (0.98) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL7196327 | 0.99 | CYSLTR1 (0.98) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL10873776 | 0.98 | CYSLTR1 (0.96) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL4348786 | 0.98 | CYSLTR1 (0.96) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL10827442 | 0.98 | CYSLTR1 (0.96) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10769450 | 0.97 | CYSLTR1 (0.94) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL7751090 | 0.89 | CYSLTR1 (0.80) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10639082 | 0.89 | CYSLTR1 (0.80) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10638680 | 0.88 | GPBAR1 (0.78) | GPBAR1CYSLTR1CYSLTR2MAPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| US-7365099-B2 | Reducing lipoxygenase activity by administering enzyme inhibitor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-04-29 | — | — | US | claimed |
| US-20040146539-A1 | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits | GUPTA SHYAM K (US) | 2004-07-29 | — | — | US | claimed |
| US-20020197301-A1 | Animal body fat control | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-12-26 | — | — | US | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0110405-B1 | ANTIINFLAMMATORY/ANTIALLERGIC COMPOUNDS | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1990-12-27 | — | — | EP | claimed |
| US-4794188-A | LIPOXYGENASE INHIBITORS | USV PHARMACEUTICAL CORPORATION (US) | 1988-12-27 | — | — | US | claimed |
| EP-0181568-A2 | Anti-inflammatory/anti-allergic compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1986-05-21 | — | — | EP | claimed |
| US-4567184-A | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies | USV PHARMACEUTICAL CORPORATION (US) | 1986-01-28 | — | — | US | claimed |
| EP-0110405-A2 | Antiinflammatory/antiallergic compounds | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1984-06-13 | — | — | EP | claimed |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240307414-A1 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-09-19 | — | — | US | disclosed |
| CN-117844807-A | Exon skipping compositions for the treatment of muscular dystrophy | 萨勒普塔医疗公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| US-4794188-A | LIPOXYGENASE INHIBITORS | USV PHARMACEUTICAL CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| EP-0234500-A1 | Antiasthma inhalation compositions | RORER PHARMACEUTICAL CORPORATION (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4625034-A | 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORP. (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0190722-A2 | Dihydro and tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORPORATION (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | GPBAR1 1/4885CYSLTR1 2/4885CYSLTR2 3/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | GPBAR1 70/4885CYSLTR1 3/4885CYSLTR2 2/4885 |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | PSMB3, THRB, GRIN2B | GPBAR1 376/4885CYSLTR1 1366/4885CYSLTR2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.